Get the Stockscreener App
1.66
1.84%
0.03
Pre-market:
1.67
0.01
+0.60%
Biovie Inc stock is traded at $1.66, with a volume of 52,595.
It is up +1.84% in the last 24 hours and up +26.72% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.63
Open:
$1.63
24h Volume:
52,595
Relative Volume:
0.59
Market Cap:
$12.52M
Revenue:
-
Net Income/Loss:
$-19.92M
P/E Ratio:
-0.3886
EPS:
-4.2716
Net Cash Flow:
$-20.51M
1W Performance:
-0.60%
1M Performance:
+26.72%
6M Performance:
+16.08%
1Y Performance:
+45.61%
1-Day Range:
$1.63
$1.70
1-Week Range:
$1.5506
$1.7576
52-Week Range:
$0.88
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
1.66 | 12.52M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BIVI Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating ExpensesAdjusted Earnings Analysis - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss Than Expected as Pipeline Progress ContinuesEnergy Earnings Report - newsline.com
BIVI Q1 2026 Earnings: EPS Beat Amid Clinical Progress; Stock DeclinesShare Repurchase Impact - newsline.com
Law firm investigates BioVie officers for possible breach of duties to shareholders - Pluang
BioVie Inc. (BIVI) Q1 2026 Earnings: EPS Surpasses Estimates Despite Ongoing Revenue VoidEarnings Call Highlights - newsline.com
BIVI Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines on No Revenue StreamTrough Earnings Signal - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Barchart.com
Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases - Kavout
BIVI: Imminent clinical data for Parkinson's and long COVID could unlock major commercial opportunities - TradingView
BioVie Deadline Alert - TMX Newsfile
BioVie Inc. Warrant (BIVIW) Holds Steady Near Support – Waiting for a CatalystProfitability Factor - newsline.com
BioVie: Long COVID trial fully enrolled – ICYMI - Yahoo Finance
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
BioVie Inc. (BIVI) Hovers Near Key Support Levels as Stock Remains FlatAdvance Decline Line - The Legal Advocate
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 - Weekly Voice
BioVie to highlight neuro and liver disease programs in June 2 investor webinar - Proactive financial news
BioVie Inc. (BIVI) Declines 5.26%, Testing Key Support Near $1.37Dealer Gamma - The Legal Advocate
BioVie Inc. (BIVI) Declines 5.26%, Testing Critical Support Near $1.37BPI Bear Confirmed - The Legal Advocate
BIVI Q1 2026 Earnings: EPS Beats Estimates Despite No Revenue, Stock DropsEstimate Accuracy - The Legal Advocate
Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news
BioVie completes enrollment in Long COVID trial as need for treatments grows - Proactive financial news
BioVie Inc. (BIVI) Faces Selling Pressure as Shares Slide 5.9%Momentum Trade - The Legal Advocate
BioVie (BIVI) Completes Enrollment for Phase 2 Trial of Bezister - GuruFocus
BioVie completes enrollment in Phase 2 Long COVID trial - Yahoo! Finance Canada
BioVie completes enrollment in Long COVID treatment trial - Investing.com
BioVie completes enrollment in Long COVID treatment trial By Investing.com - Investing.com Nigeria
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - The Manila Times
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of - GlobeNewswire
BioVie Inc. (BIVI) Gains 2.7% as Shares Test Near-Term ResistanceQuality Factor - The Legal Advocate
BioVie Inc. (BIVI) Q1 2026 Earnings: Narrowing Losses and Clinical Progress Buoy Investor SentimentStrong Earnings Momentum - Newser
BioVie Inc.Common stock (NQ: BIVI - The Chronicle-Journal
BioVie (BIVI) Delivers Q1 2026 Beat — EPS $-0.70 vs $-0.74 ExpectedEarnings Deceleration Risk - newsline.com
BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3 - Bez Kabli
BioVie (BIVI) Rallies +1.53% as Bulls Target $1.40 2026-05-20Dividend Arbitrage - Newser
BioVie completes final patient visit in Parkinson's drug trial - Proactive financial news
BioVie (BIVI) Completes Patient Evaluations for Parkinson's Tria - GuruFocus
BioVie completes patient visits in Parkinson’s disease trial By Investing.com - Investing.com Nigeria
BioVie completes patient visits in Parkinson’s disease trial - Investing.com
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):